Acadia PharmaceuticalsACAD
Recorded

Acadia Pharmaceuticals 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 1 minParticipants15

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, and welcome to ACADIA Pharmaceuticals third quarter earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, please press star one on your telephone keypad. I would now like to turn the conference over to Al Kildani, Senior Vice President, Investor Relations and Corporate Communications.

Al KildaniSVP of Investor Relations and Corporate Communications

You may begin. Good afternoon, and thank you for joining us on today's call to discuss ACADIA's third quarter 2026 financial results.

Al KildaniSVP of Investor Relations and Corporate Communications

Joining me on the call today from ACADIA are Catherine Owen Adams, our Chief Executive Officer, who will provide some opening remarks, followed by Tom Garner, our Chief Commercial Officer, who will discuss our commercial brands DAYBUE and NUPLAZID. Also joining us today is Dr. Sanjeev Pathak, SVP and Head of Clinical Development, who will provide an update on our pipeline programs, and Mark Schneyer, our Chief Financial Officer, who will review the financial highlights. Catherine will then provide some closing remarks before we open up the call for your questions. We are using supplemental slides, which are available on our website in the Events and Presentations section. On today's call, both GAAP and non-GAAP financial measures will be discussed, including non-GAAP NUPLAZID net sales and non-GAAP total revenues.

Al KildaniSVP of Investor Relations and Corporate Communications

The non-GAAP financial measures that are also referred to as adjusted financial measures pertain only to NUPLAZID sales in 2025 and their impact on total revenues. All references to non-GAAP are reconciled with the most directly comparable GAAP financial measures in our earnings press release and slide presentation, which has been posted on the Investors page of the company's website. Before proceeding, I would like to remind you that during our call today, we will be making several forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including goals, expectations, plans, prospects, growth potential, timing of events, future results, and financial guidance, are based on current information, assumptions, and expectations that are inherently subject to change and involve several risks and uncertainties that may cause results to differ materially.

Al KildaniSVP of Investor Relations and Corporate Communications

These factors and other risks associated with our business can be found in our filings made with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of today's date, and we assume no obligation to update or revise these forward-looking statements as circumstances change, except as required by law. I'll now turn the call over to Catherine for opening remarks.

Catherine Owen AdamsCEO

Thank you, Al, and good afternoon, everyone. Quarter three was another strong quarter for ACADIA, one that demonstrates the strength of our commercial foundation and the progress we are making to translate that strength into our next chapter of growth. In the third quarter, we delivered total revenues of $342 million, representing 22% year-over-year growth on an adjusted basis. DAYBUE delivered record net sales of $140 million, up 39% year-over-year. DAYBUE STIX is expanding our opportunity in several different ways. Current patients who want to switch to STIX, new patients who are trying DAYBUE for the first time, and patients who previously stopped treatment and are coming back to try again with STIX. Given this momentum, we are raising our 2026 DAYBUE guidance, and we remain confident that we can reach $700 million in DAYBUE sales by the end of 2028.

Catherine Owen AdamsCEO

We also achieved an important IP milestone during the quarter, receiving a USPTO notice of allowance for an important new patent covering the weight-banded dosing regimen used in both DAYBUE oral solution and DAYBUE STIX. Following issuance with pediatric exclusivity, the patent is expected to provide U.S. protection for both formulations of DAYBUE through March 2041, extending patent protections by nearly five years. Following the successful completion of our phase III trial for DAYBUE in Japan, we are focused on identifying the right distribution partner while preparing for an expected 2027 regulatory submission to support market entry and remain committed to bringing DAYBUE to patients there. NUPLAZID delivered $202 million in net sales, up 12% year-over-year on an adjusted basis, with virtually all of that growth driven by patient demand through volume.

Catherine Owen AdamsCEO

As we approach the end of the year, we are narrowing our NUPLAZID guidance and remain confident that we are on track toward our ambition to reach approximately $1 billion in NUPLAZID net sales by the end of 2028. Tom will provide additional color on the commercial drivers behind our performance on both brands. Turning to our pipeline, the phase II portion of our RADIANT program of remlifanserin in Alzheimer's disease psychosis narrowly missed statistical significance on the primary endpoint, but achieved our goals with the study to clarify the dose to advance into phase III and generate insights needed to optimize the phase III portion of the program.

Catherine Owen AdamsCEO

At the 60 milligram dose, efficacy was observed across all four psychosis scales assessed in the full study population, with increasing separation from placebo through the six-week treatment period on both the primary and key secondary endpoints, along with a favorable safety and tolerability profile similar to placebo. Based on these findings, we are focusing our phase III program on the 60 milligram dose and taking additional steps designed to optimize for potential positive phase III outcomes. The more we have learned from these data, the more confident we have become in the path forward for the program. The findings from our RADIANT Phase 2 in ADP also reinforce our confidence in the opportunity in Lewy body dementia psychosis.

Catherine Owen AdamsCEO

We remain excited about the potential for remlifanserin in this population and are pleased to announce that we expect phase II results from the ILLUMERA study in the fourth quarter of 2027. Taken together, remlifanserin represents an important potential growth franchise across both ADP and LBDP, both areas of huge unmet medical need, with an approximately $4 billion combined peak sales opportunity. Our priority now is to generate the clinical evidence needed to validate that opportunity. Beyond remlifanserin, we are advancing our broader pipeline of promising programs that we believe have the potential to address significant unmet needs and create long-term value. An additional data readout for our NORLIGHT phase II study of ACP-211, our once-a-day oral deuterated form of R-norketamine for the treatment of major depressive disorder, is now expected in the second half of 2027.

Catherine Owen AdamsCEO

We believe ACP-211 has the potential to address significant unmet need in major depressive disorder, specifically around the patient and clinician experience, and we look forward to sharing more on this program as we move into 2027. When you step back and look at the full picture, remlifanserin in ADP and LBDP, ACP-211 in MDD, and some of our earlier stage programs, we see multiple independent paths to add potential value across large, high unmet need markets, representing combined peak sales potential of approximately $11 billion. The opportunity is significant, but our conviction and investment will continue to be guided by the evidence each program generates. Before I hand over, a brief update on our R&D leadership. Today's pipeline update will be delivered by Dr. Sanjeev Pathak, our Senior Vice President and Head of Clinical Development.

Catherine Owen AdamsCEO

Many of you will know Sanjeev from our R&D day or from prior investor conferences, and I think you'll find his perspective as a double board certified psychiatrist on the remlifanserin data particularly valuable. As we indicated in April, Dr. Liz Thompson has now retired from her role as Head of R&D. Liz has made an extraordinary contribution during her tenure at ACADIA, and we are deeply grateful for her leadership. She remains engaged with us as a valued consultant, and we wish her very well in her retirement. We do expect to announce our new Head of R&D in the near term. In the meantime, R&D leadership responsibilities are being shared by Sanjeev, along with other members of our R&D leadership team. With that, I'll hand the call over to Tom to walk through our commercial performance in detail.

Tom GarnerChief Commercial Officer

Thank you, Catherine, and good afternoon, everyone. I'm pleased to walk you through what was another strong quarter for the commercial business. Starting with DAYBUE, Q3 marked yet another record quarter for the brand with $140 million in net sales, representing 39% growth year-over-year, with almost all of that being driven by volume. That's a result that we're particularly proud of, as it not only reflects the continued execution of our commercial team, but also the deepening position DAYBUE holds as the foundational standard of care for Rett syndrome. DAYBUE STIX continued to be an important contributor to growth in Q3. Now with approximately six months of commercial experience, we're seeing increasing utilization across the patient base and continued adoption in both Centers of Excellence and community practices.

Tom GarnerChief Commercial Officer

Over 50% of all U.S. DAYBUE patients were receiving STIX by the end of Q3, with these patients generally utilizing doses consistent with or somewhat higher than what we have seen historically with DAYBUE liquid. We are also encouraged by the early experience with patient restarts, which expands the growth opportunity for DAYBUE beyond naive patients alone. Patients who previously discontinued therapy represent an opportunity for re-engagement, and STIX provides caregivers with a compelling reason to reconsider treatment with a different formulation. While the initial pace of STIX conversion will naturally moderate as the launch matures, we believe continued new patient uptake and restarts provide two distinct opportunities to drive sustained growth going forwards. Turning to DAYBUE outside the U.S., Q3 was a landmark quarter. We received European Commission approval for DAYBUE, making it the first and only approved treatment for the neurobehavioral symptoms of Rett syndrome in the EU.

Tom GarnerChief Commercial Officer

This is an important milestone for patients, families, and treating physicians who previously had no approved treatment options available. We launched commercially in Germany in early October, and the early response from Rett-treating physicians has been encouraging. We are already seeing that initial interest translate into new patients receiving commercial product, in addition to those patients converting from our compassionate use program. As a reminder, Germany allows us to launch at a freely set price while reimbursement negotiations are completed, so we were able to move quickly to make DAYBUE available to these patients. Looking across the rest of the EU, we plan to submit reimbursement dossiers for our key planned launch countries before year-end to drive additional commercial access to DAYBUE.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day